Bart Rijnders

16.2k citations
143 papers · 7.6k · 2 hit papers · h-index 37

Impact in

Papers in

  • Infectious Diseases 87
    • Antifungal resistance and susceptibility 50
    • HIV/AIDS drug development and treatment 16
    • SARS-CoV-2 and COVID-19 Research 12
    • COVID-19 Clinical Research Studies 7
  • Epidemiology 41
    • Fungal Infections and Studies 22
Co-authors
David K. Warren (2 shared papers)Donald E. Craven (2 shared papers)Issam Raad (2 shared papers)Emilio Bouza (2 shared papers)Patricia M. Flynn (2 shared papers)Robert J. Sherertz (2 shared papers)Michael Allon (2 shared papers)Naomi P. O’Grady (2 shared papers)
Journals
Clinical Infectious Diseases (20 papers)Journal of Antimicrobial Chemotherapy (12 papers)AIDS (8 papers)Journal of Clinical Microbiology (7 papers)Mycoses (5 papers)
Partner nations
NetherlandsBelgiumUnited States

In The Last Decade

Bart Rijnders

138 papers receiving 7.4k citations

Bart Rijnders's Hit Papers

Clinical Implications of Azole Resistance inAspergillus fumigatus, the Netherlands, 2007–2009 2011 · 382 citations
3820+5+11Years since publication50010001.5k2.0k2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2011 Emerging infectious diseases
  2. 2009 Clinical Infectious Diseases

Peers

Bart Rijnders
Comparison fields: 5 of 155
  • Emergency Medical Services 1.7k
  • Infectious Diseases 3.8k
  • Applied Microbiology and Biotechnology 226
  • Epidemiology 2.5k
  • Critical Care and Intensive Care Medicine 336
Replace Tony M. Korman with:
Tony M. Korman Australia
Roy F. Chemaly United States
Arthur E. Brown United States
Peter H. Gilligan United States
Kenneth V. I. Rolston United States
Sílvia Figueiredo Costa Brazil
Stephen B. Greenberg United States
Peter Speelman Netherlands
Annelies Verbon Netherlands
Phyllis Della‐Latta United States
Bart Rijnders relative to Tony M. Korman Australia Tony M. Korman's profile →
Citations per field
00.5×5×11.0×
Tony M. Korman · 1×
Citations per year

Countries citing papers authored by Bart Rijnders

Since Specialization
Citations

This map shows the geographic impact of Bart Rijnders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Rijnders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Rijnders more than expected).

Fields of papers citing papers by Bart Rijnders

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Rijnders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Rijnders. The network helps show where Bart Rijnders may publish in the future.

Co-authors

The 25 scholars most cited alongside Bart Rijnders, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bart Rijnders Line = papers co-authored together Bart Rijnders links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 143 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
Clinical Infectious Diseases ·Leonard A. Mermel, Michael Allon, Emilio Bouza, Donald E. Craven, Patricia M. Flynn, Naomi P. O’Grady, Issam Raad, Bart Rijnders, Robert J. Sherertz, David K. Warren
Hit paper breakdown →		20092625
2
Clinical Implications of Azole Resistance inAspergillus fumigatus, the Netherlands, 2007–2009
Emerging infectious diseases ·Jan W. M. van der Linden, Eveline Snelders, Greetje A. Kampinga, Bart Rijnders, Eva Mattsson, Y. J. Debets-Ossenkopp, Ed J. Kuijper, Frank H. van Tiel, Willem J. G. Melchers, Paul E. Verweij
Hit paper breakdown →		2011382
3
Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles
Clinical Infectious Diseases ·Jan W. M. van der Linden, Simone M. T. Camps, Greetje A. Kampinga, Jan P. Arends, Y. J. Debets-Ossenkopp, P. J. A. Haas, Bart Rijnders, Ed J. Kuijper, Frank H. van Tiel, János Varga, Anna Karawajczyk, Jan Zoll, Willem J. G. Melchers, Paul E. Verweij
2013280
4
Prevention of Catheter-Related Bacteremia with a Daily Ethanol Lock in Patients with Tunnelled Catheters: A Randomized, Placebo-Controlled Trial
PLoS ONE ·Lennert Slobbe, Jeanette K. Doorduijn, Pieternella J. Lugtenburg, Abdelilah el Barzouhi, Eric Boersma, Willem B. van Leeuwen, Bart Rijnders
2010237
5
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
Nature Communications ·Corine H. GeurtsvanKessel, Nisreen M.A. Okba, Zsὁfia Iglὁi, Susanne Bogers, Carmen W.E. Embregts, Brigitta M. Laksono, Lonneke Leijten, Casper Rokx, Bart Rijnders, Janette Rahamat‐Langendoen, Johannes P. C. van den Akker, Jeroen J. A. van Kampen, Annemiek A. van der Eijk, Rob van Binnendijk, Bart L. Haagmans, Marion Koopmans
2020235
6
Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study
Clinical Infectious Diseases ·Pieter P. A. Lestrade, Robbert G. Bentvelsen, Alexander Schauwvlieghe, Steven Schalekamp, Walter J. F. M. van der Velden, Ed J Kuiper, Judith van Paassen, Ben van der Hoven, Henrich A. van der Lee, Willem J. G. Melchers, A F de Haan, Hans L van der Hoeven, Bart Rijnders, Martha T. van der Beek, Paul E. Verweij
2018230
7
Aerosolized Liposomal Amphotericin B for the Prevention of Invasive Pulmonary Aspergillosis during Prolonged Neutropenia: A Randomized, Placebo‐Controlled Trial
Clinical Infectious Diseases ·Bart Rijnders, Jan J. Cornelissen, Lennert Slobbe, Martin Becker, Jeanette K. Doorduijn, Wim C.J. Hop, Elisabeth J. Ruijgrok, Bob Löwenberg, Arnold G. Vulto, Pieternella J. Lugtenburg, Siem de Marie
2008221
8
Influenza-associated Aspergillosis in Critically Ill Patients
American Journal of Respiratory and Critical Care Medicine ·Frank L. van de Veerdonk, Eva Kolwijck, Pieter P. A. Lestrade, Caspar J. Hodiamont, Bart Rijnders, Judith van Paassen, Pieter‐Jan Haas, Claudy Oliveira dos Santos, Greetje A. Kampinga, Dennis C. J. J. Bergmans, Karin van Dijk, Anton F. J. de Haan, Jaap van Dissel, Hans G. van der Hoeven, Paul E. Verweij
2017165
9
Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial
Journal of Antimicrobial Chemotherapy ·Bart Rijnders, Eric Van Wijngaerden, Stefaan J. Vandecasteele, Marguerite Stas, Willy Peetermans
2004137
10
Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment
Current Opinion in Infectious Diseases ·Lore Vanderbeke, Isabel Spriet, Christine Breynaert, Bart Rijnders, Paul E. Verweij, Joost Wauters
2018121
11
Validation of a New Aspergillus Real-Time PCR Assay for Direct Detection of Aspergillus and Azole Resistance of Aspergillus fumigatus on Bronchoalveolar Lavage Fluid
Journal of Clinical Microbiology ·Ga‐Lai M. Chong, Wendy W. J. van de Sande, Gijs Dingemans, Giel R. Gaajetaan, Alieke G. Vonk, Marie‐Pierre Hayette, Dennis W. E. van Tegelen, Guus Simons, Bart Rijnders
2015118
12
PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay ® in 201 patients with haematological disease suspected for invasive aspergillosis
Journal of Antimicrobial Chemotherapy ·Ga‐Lai M. Chong, Martha T. van der Beek, Peter A. von dem Borne, Jerina Boelens, Eva Steel, Greetje A. Kampinga, Lambert F. R. Span, Katrien Lagrou, Johan Maertens, Gijs Dingemans, Giel R. Gaajetaan, Dennis W. E. van Tegelen, Jan J. Cornelissen, Alieke G. Vonk, Bart Rijnders
2016111
13
Catheter‐Tip Colonization as a Surrogate End Point in Clinical Studies on Catheter‐Related Bloodstream Infection: How Strong Is the Evidence?
Clinical Infectious Diseases ·Bart Rijnders, Eric Van Wijngaerden, Willy Peetermans
2002105
14
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
Clinical Infectious Diseases ·Andreas H. Groll, Bart Rijnders, Thomas J. Walsh, Jill Adler‐Moore, Russell E. Lewis, Roger J. M. Brüggemann
201997
15
Reliability of the ica, aap and atlE genes in the discrimination between invasive, colonizing and contaminant Staphylococcus epidermidis isolates in the diagnosis of catheter—related infections
Clinical Microbiology and Infection ·Stefaan J. Vandecasteele, Willy Peetermans, Rita Merckx, Bart Rijnders, Johan Van Eldere
200391
16
Watchful waiting versus immediate catheter removal in ICU patients with suspected catheter-related infection: a randomized trial
Intensive Care Medicine ·Bart Rijnders, Willy Peetermans, Charles Verwaest, Alexander Wilmer, Eric Van Wijngaerden
200488
17
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study
The Lancet Infectious Diseases ·Brooke E Nichols, Charles A. Boucher, Marc van der Valk, Bart Rijnders, David van de Vijver
201683
18
Outcome and Medical Costs of Patients with Invasive Aspergillosis and Acute Myelogenous Leukemia–Myelodysplastic Syndrome Treated with Intensive Chemotherapy: An Observational Study
Clinical Infectious Diseases ·Lennert Slobbe, Suzanne Polinder, Jeanette K. Doorduijn, Pieternella J. Lugtenburg, Abdelilah el Barzouhi, Ewout W. Steyerberg, Bart Rijnders
200879
19
Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
The Lancet HIV ·Ingeborg E A Wijting, Casper Rokx, Charles A. Boucher, Jeroen J. A. van Kampen, Suzan D. Pas, Theodora de Vries-Sluijs, Carolina A. M. Schurink, Hannelore I. Bax, Maarten Derksen, Eleni‐Rosalina Andrinopoulou, Marchina van der Ende, Eric C. M. Van Gorp, Jan Nouwen, Annelies Verbon, Wouter F.W. Bierman, Bart Rijnders
201776
20
High Prevalence of Sexually Transmitted Infections in HIV-Infected Men During Routine Outpatient Visits in the Netherlands
Sexually Transmitted Diseases ·Marlies Heiligenberg, Bart Rijnders, Maarten F. Schim van der Loeff, Henry J.C. de Vries, W I van der Meijden, Suzanne E. Geerlings, H Fennema, Maria Prins, Jan M. Prins
201172

About Bart Rijnders

Bart Rijnders is a scholar working on Infectious Diseases, Epidemiology, Hepatology, Emergency Medical Services and Small Animals, having authored 143 papers that have together received 7.6k indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (50 papers), Fungal Infections and Studies (22 papers), Hepatitis C virus research (16 papers), HIV/AIDS drug development and treatment (16 papers), Central Venous Catheters and Hemodialysis (12 papers), SARS-CoV-2 and COVID-19 Research (12 papers), Infectious Diseases and Mycology (8 papers) and COVID-19 Clinical Research Studies (7 papers). The work is most often cited by research in Emergency Medical Services (1.7k citations), Infectious Diseases (3.8k citations), Applied Microbiology and Biotechnology (226 citations), Epidemiology (2.5k citations) and Critical Care and Intensive Care Medicine (336 citations). Bart Rijnders has collaborated with scholars based in Netherlands, Belgium and United States. Frequent co-authors include David K. Warren, Donald E. Craven, Issam Raad, Emilio Bouza, Patricia M. Flynn, Robert J. Sherertz, Michael Allon, Naomi P. O’Grady, Leonard A. Mermel and Paul E. Verweij. Their work appears in journals such as Clinical Infectious Diseases, Journal of Antimicrobial Chemotherapy, AIDS, Journal of Clinical Microbiology and Mycoses.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tony M. KormanBreakdown of academic impact, for papers by Roy F. ChemalyBreakdown of academic impact, for papers by Arthur E. BrownBreakdown of academic impact, for papers by Peter H. GilliganBreakdown of academic impact, for papers by Kenneth V. I. RolstonBreakdown of academic impact, for papers by Sílvia Figueiredo CostaBreakdown of academic impact, for papers by Stephen B. GreenbergBreakdown of academic impact, for papers by Peter SpeelmanBreakdown of academic impact, for papers by Annelies VerbonBreakdown of academic impact, for papers by Phyllis Della‐Latta